122 related articles for article (PubMed ID: 14761918)
1. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.
El-Tamer M; Russo D; Troxel A; Bernardino LP; Mazziotta R; Estabrook A; Ditkoff BA; Schnabel F; Mansukhani M
Ann Surg Oncol; 2004 Feb; 11(2):157-64. PubMed ID: 14761918
[TBL] [Abstract][Full Text] [Related]
2. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Lee JS; Wacholder S; Struewing JP; McAdams M; Pee D; Brody LC; Tucker MA; Hartge P
J Natl Cancer Inst; 1999 Feb; 91(3):259-63. PubMed ID: 10037104
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
5. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
7. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
Lee LJ; Alexander B; Schnitt SJ; Comander A; Gallagher B; Garber JE; Tung N
Cancer; 2011 Jul; 117(14):3093-100. PubMed ID: 21264845
[TBL] [Abstract][Full Text] [Related]
9. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
[TBL] [Abstract][Full Text] [Related]
10. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
[TBL] [Abstract][Full Text] [Related]
11. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
12. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
13. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
Bernholtz S; Jakobson-Setton A; Korach J; Ben Baruch G; Laitman Y; Friedman E
Breast Cancer Res Treat; 2012 Feb; 131(3):981-5. PubMed ID: 21984204
[TBL] [Abstract][Full Text] [Related]
14. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips KA; Nichol K; Ozcelik H; Knight J; Done SJ; Goodwin PJ; Andrulis IL
J Natl Cancer Inst; 1999 Mar; 91(5):469-73. PubMed ID: 10070948
[TBL] [Abstract][Full Text] [Related]
15. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
16. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
[TBL] [Abstract][Full Text] [Related]
17. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
[TBL] [Abstract][Full Text] [Related]
18. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
